# Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

> **NCT02259972** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 63 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 113823 solution
- **DRUG:** BI 113823 tablet
- **DRUG:** Placebo
- **OTHER:** High fat, high calorie breakfast

## Key facts

- **NCT ID:** NCT02259972
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2014-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259972, "Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02259972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*